Price T Rowe Associates Inc Oncocyte Corp Transaction History

Price T Rowe Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $4,281 - $7,616	-4,978 Reduced 11.97%	36,600 $33,000
Q1 2022 May 16, 2022	BUY	$1.15 - $2.25 $16,675 - $32,625	14,500 Added 53.55%	41,578 $62,000
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $4,080 - $7,180	-2,000 Reduced 6.88%	27,078 $59,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $706 - $1,178	200 Added 0.69%	29,078 $104,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $6.0 $69,349 - $110,370	-18,395 Reduced 38.91%	28,878 $166,000
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $112,982 - $307,274	47,273 New	47,273 $245,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $331M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.